What's in The Lymphoma Academic Research Organisation's pipeline?

The Lymphoma Academic Research Organisation has 18 drugs in our index: 1 marketed, 0 filed, 6 in Phase 3, 6 in Phase 2, 4 in Phase 1.

Which companies overlap with The Lymphoma Academic Research Organisation's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Universität des Saarlandes, Ludwig-Maximilians - University of Munich, AryoGen Pharmed Co., Astellas Pharma Global Development, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/the-lymphoma-academic-research-organisation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

The Lymphoma Academic Research Organisation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Lymphoma Academic Research Organisation pipeline: 1 marketed, 0 filed, 6 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 6 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Vinblastin	Vinblastin	marketed		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1	Oncology
Mosunetuzumab (SC)	Mosunetuzumab (SC)	phase 3	Bispecific antibody (T-cell engager)	CD20 and CD3	Oncology
Rituximab - CVP	Rituximab - CVP	phase 3	Monoclonal antibody + chemotherapy combination	CD20	Oncology
R-CHOP / R-HAD	R-CHOP / R-HAD	phase 3	Monoclonal antibody + chemotherapy combination	CD20 (rituximab component)	Oncology
RCHOP21	RCHOP21	phase 3	Chemotherapy	CD20	Oncology
Romidepsin + CHOP	Romidepsin + CHOP	phase 3	HDAC inhibitor + chemotherapy combination	Histone deacetylases (HDAC)	Oncology
Rituximab - CHOP	Rituximab - CHOP	phase 3	Monoclonal antibody (anti-CD20)	CD20	Oncology

Therapeutic area mix

Oncology · 9
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Universität des Saarlandes · 2 shared drug classes
Ludwig-Maximilians - University of Munich · 2 shared drug classes
AryoGen Pharmed Co. · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
BeiGene · 1 shared drug class
Associazione Italiana per lo Studio del Pancreas · 1 shared drug class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The Lymphoma Academic Research Organisation:

Cite this brief

Drug Landscape (2026). The Lymphoma Academic Research Organisation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-lymphoma-academic-research-organisation. Accessed 2026-05-16.